In a cerebrospinal fluid (CSF) substudy, participants receiving semaglutide exhibited modest yet statistically significant reductions (in the range of 10% or less) in several key biomarkers associated with Alzheimers disease (AD) pathology and neurodegeneration, including phosphorylated tau181 (p-tau181), phosphorylated tau217 (p-tau217), total tau, and the neuroinflammatory marker YKL-40 levels
The persistence of side effects depends on several factors: your starting dose, how quickly your dose increases, your genetics, and your lifestyle choices
For someone at 180 pounds, that's 126 to 180 grams of protein daily
Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study
And for patients who have previously undergone bariatric surgery, medication can help restore appetite control and support ongoing success
Wang, Volkow, et al